Billy Evans’ Haemanthus has lost its CTO and reportedly has yet to launch a commercial product

Joseph LaChapelle told Forbes he resigned from Billy Evans’ Haemanthus in March over a conflict involving an earlier startup. But a person who spoke with Evans told Forbes that Evans said he let the CTO go. LaChapelle is named on a patent assigned to Haemanthus. Fortune reported Oct. 25 that the company had yet to launch a commercial product or disclose independently validated diagnostic results, despite its claims about laser-based disease detection.